Abstract:
A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of:(a) a pellet comprising an inert core component, a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and(b) a single layer of coating on said pellet which comprises a layer of an enteric coating agent.
Abstract:
A method for manufacturing an inductor with resonant frequency and Q value increased in semiconductor process can reduce substrate coupling effect, because (an) air layer(s) is/are formed just under a spiral metal layer which functions as an inductor. In addition, part of the substrate material still remains around the air layer(s), which can be used as a support for the spiral metal layer. Therefore, a problem causing the above-mentioned spiral metal layer to collapse will never occur.
Abstract:
A flash electrical erasable programmable read only memory structure that utilizes hot carrier injection for programming and negative gate voltage to carry out channel erase operations. Characteristic of the memory structure includes a triple well structure having a P-well and an N-well located within a P-type substrate, wherein the N-well isolated the P-well from the P-type substrate. Therefore, an independently isolated triple well structure is established during memory erase operation.
Abstract:
A method for manufacturing EPROM tunnel oxide cell having a damage-free source region. The method comprises the step of providing a substrate having a device region formed thereon, and then forming an ion-implanted region in the device area. Next, a gate oxide layer is formed over the substrate. Subsequently, a floating gate, a dielectric layer, a control gate and an oxide layer are sequentially formed above the substrate. This invention utilizes the implantation of a moderately heavy dose of ions into a device area prior to the formation of the gate oxide layer, so that a thicker gate oxide layer is formed above the source region. Hence, when the first polysilicon layer is etched in a subsequent self-aligned etching operation to establish the common source region, the thicker gate oxide layer can serve as a protective layer for the source region.
Abstract:
A once-a-day controlled release diltiazem formulation is described which includes: (a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder and a second layer which comprises a polymeric membrane which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem; and (c) a unit dose containment system.
Abstract:
An method for the formation of polycide used for the gate electrode or interconnection metallization in semiconductor integrated circuit devices has been developed. The polycide is formed from doped amorphous silicon deposited from SiH.sub.4 and PH.sub.3 and tungsten silicide deposited from dichlorosilane (SiH.sub.2 Cl.sub.2 and WF.sub.6, followed by conventional RIE patterning. The key feature, annealing of the polycide structure by a combination of RTA (Rapid Thermal Anneal) in a nitrogen ambient, and then a furnace anneal in an oxygen ambient prevents deleterious sidewall growth on the polycide structure and results in a highly manufacturable process having high yield.
Abstract:
A controlled release pharmaceutical tablet having at least one passageway, said tablet having:(a) a compressed core which comprises:(i) a medicament;(ii) an amount of a water soluble osmotic agent which is effective to cause the medicament to be delivered from said passageway in the presence of aqueous media;(iii) a water-swellable pharmaceutically acceptable polymer; and(b) a membrane coating around said core tablet which comprises a water insoluble pharmaceutically acceptable polymer.
Abstract:
A once-a-day controlled release diltiazem formulation is described which includes:(a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and(b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder and a second layer which comprises a polymeric membrane which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem; and(c) a unit dose containment system.
Abstract:
An energy saving air conditioning system is disclosed which provides different air conditioning modes, including a closed-loop mode, an open-loop mode, and a partial-loop mode, for controlling the environment in a high-density apparatus room. The energy saving air conditioning system uses a cloud operating center to monitor the temperature and the moisture inside and outside the high-density apparatus room. The cloud operating system dynamically selects the air conditioning mode in such a manner that energy can be saved and the environment in the high-density apparatus room can be optimally managed.
Abstract:
A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.